Följ
Kristian Wachtell
Kristian Wachtell
Oslo University Hospital
Verifierad e-postadress på wachtell.net - Startsida
Titel
Citeras av
Citeras av
År
Heart disease and stroke statistics—2016 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
circulation 133 (4), e38-e360, 2016
41175*2016
Heart disease and stroke statistics—2014 update: a report from the American Heart Association
AS Go, D Mozaffarian, VL Roger, EJ Benjamin, JD Berry, MJ Blaha, S Dai, ...
circulation 129 (3), e28-e292, 2014
27867*2014
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
AB Rossebø, TR Pedersen, K Boman, P Brudi, JB Chambers, K Egstrup, ...
New England journal of medicine 359 (13), 1343-1356, 2008
18782008
Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in …
K Wachtell, M Lehto, E Gerdts, MH Olsen, B Hornestam, B Dahlöf, H Ibsen, ...
Journal of the American College of Cardiology 45 (5), 712-719, 2005
11792005
Prognostic significance of left ventricular mass change during treatment of hypertension
RB Devereux, K Wachtell, E Gerdts, K Boman, MS Nieminen, ...
Jama 292 (19), 2350-2356, 2004
10602004
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
H Ibsen, MH Olsen, K Wachtell, K Borch-Johnsen, LH Lindholm, ...
Hypertension 45 (2), 198-202, 2005
984*2005
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
K Wachtell, H Ibsen, MH Olsen, K Borch-Johnsen, LH Lindholm, ...
Annals of internal medicine 139 (11), 901-906, 2003
7622003
Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
RB Devereux, B Dahlöf, E Gerdts, K Boman, MS Nieminen, ...
Circulation 110 (11), 1456-1462, 2004
6922004
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
MH Olsen, SY Angell, S Asma, P Boutouyrie, D Burger, JA Chirinos, ...
The Lancet 388 (10060), 2665-2712, 2016
6672016
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study
LH Lindholm, H Ibsen, K Borch-Johnsen, MH Olsen, K Wachtell, B Dahlöf, ...
Journal of hypertension 20 (9), 1879-1886, 2002
5402002
Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis
MP Schneider, TA Hua, M Böhm, K Wachtell, SE Kjeldsen, RE Schmieder
Journal of the American College of Cardiology 55 (21), 2299-2307, 2010
5012010
Risk prediction is improved by adding markers of subclinical organ damage to SCORE
T Sehestedt, J Jeppesen, TW Hansen, K Wachtell, H Ibsen, ...
European heart journal 31 (7), 883-891, 2010
4662010
Outcome of patients with low-gradient “severe” aortic stenosis and preserved ejection fraction
N Jander, J Minners, I Holme, E Gerdts, K Boman, P Brudi, JB Chambers, ...
Circulation 123 (8), 887-895, 2011
3962011
Short-and long-term cause of death in patients treated with primary PCI for STEMI
F Pedersen, V Butrymovich, H Kelbæk, K Wachtell, S Helqvist, J Kastrup, ...
Journal of the American College of Cardiology 64 (20), 2101-2108, 2014
3722014
Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension
PM Okin, K Wachtell, RB Devereux, KE Harris, S Jern, SE Kjeldsen, ...
Jama 296 (10), 1242-1248, 2006
3472006
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE …
K Wachtell, B Hornestam, M Lehto, DJ Slotwiner, E Gerdts, MH Olsen, ...
Journal of the American College of Cardiology 45 (5), 705-711, 2005
3242005
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study
K Wachtell, PM Okin, MH Olsen, B Dahlöf, RB Devereux, H Ibsen, ...
Circulation 116 (7), 700-705, 2007
3052007
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
E Gerdts, L Oikarinen, V Palmieri, JE Otterstad, K Wachtell, K Boman, ...
Hypertension 39 (3), 739-743, 2002
2922002
Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial
E Gerdts, K Wachtell, P Omvik, JE Otterstad, L Oikarinen, K Boman, ...
Hypertension 49 (2), 311-316, 2007
2792007
Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population: the LIFE study
K Wachtell, JN Bella, PR Liebson, E Gerdts, B Dahlöf, T Aalto, ...
Hypertension 35 (1), 6-12, 2000
2582000
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20